Eosinophilic Granulomatosis with Polyangiitis (Churg‐Strauss)

@article{Nguyen2018EosinophilicGW,
  title={Eosinophilic Granulomatosis with Polyangiitis (Churg‐Strauss)},
  author={Yann Nguyen and Lo{\"i}c Guillevin},
  journal={Seminars in Respiratory and Critical Care Medicine},
  year={2018},
  volume={39},
  pages={471–481}
}
&NA; Eosinophilic granulomatosis with polyangiitis (EGPA), formerly called Churg‐Strauss syndrome, is a systemic necrotizing vasculitis of small‐ and medium‐size vessels, characterized by asthma and blood eosinophilia. EGPA typically occurs in patients with preexisting asthma, and involves the skin, lungs, and peripheral nerves. Poor‐prognosis factors (i.e., involvement(s) of the gastrointestinal tract, heart, and/or kidney) have been assessed with the Five‐Factor Score (FFS). One‐third of the… 

Tables from this paper

Eosinophilic Granulomatosis with Polyangiitis: Experiences in Korean Patients
TLDR
The classification criteria for EGPA is described and recommendations for the evaluation and management of EGPA with conventional and newly suggested drugs for EGpa are described.
Eosinophilic granulomatosis with polyangiitis: modern view on pathogenesis and treatment (literature review)
TLDR
Clinical manifestations in EGPA tend to divide patients into two subset of the disease, with a predominance of vasculitic or eosinophilic manifestations, and ANCA can differentiate between these two subsets, but there is no insufficient understanding to use phenotype2tailored therapies.
Churg Strauss Syndrome
Churg Straus Syndrome – renamed as eosinophilic granulomatosis with polyangiitis (EGPA) – is a specific variant of the group of diseases characterized by necrotizing vasculitis of small and
Treatment of Eosinophilic Granulomatosis with Polyangiitis: A Review
TLDR
Characteristics of eosinophilic granulomatosis with polyangiitis are reviewed and an overview of established and novel pharmacological agents is provided.
Eosinophilic granulomatosis with polyangiitis as a rare cause of the syndrome of inappropriate antidiuretic hormone secretion
TLDR
A rare case of syndrome of the inappropriate antidiuretic hormone (ADH) secretion (SIadH) secondary to EGPA is reported, which implies a causality between two conditions.
Mepolizumab for the treatment of eosinophilic granulomatosis with polyangiitis
TLDR
The available literature supports the use of mepolizumab for the induction and maintenance of remission of refractory, relapsing, or glucocorticoid-dependent EGPA with potentially greater benefit in those who are ANCA-positive or those with greater eosinophilia (150 cells/L).
Granulomatosis with polyangiitis presenting with pachymeningitis and persistent headache
TLDR
A case of granulomatosis with polyangiitis in a patient with persistent frontal headache, for a very long time considered as migraine versus tension-type headache is reported.
Respiratory manifestations of eosinophilic granulomatosis with polyangiitis (Churg–Strauss)
TLDR
In EGPA, asthma is severe, antedates systemic manifestations by a mean of 12 years, and progresses to long-term persistent airflow obstruction despite corticosteroids in a large proportion of patients, which affects long- term management and morbidity.
Granulomatosis eosinofílica con poliangitis: reporte de un caso y revisión de la literatura
TLDR
The case of a 13 year old boy with diffi cult to control asthma and impaired general condition, which was fi nally diagnosed with EGPA, ANCA-negative, is reported.
...
...

References

SHOWING 1-10 OF 148 REFERENCES
Systemic Vasculitis with Asthma and Eosinophilia: A Clinical Approach to the Churg‐Strauss Syndrome
Drawing on our experience of 16 cases and a review of the English literature, we propose that CSS is under-diagnosed because of exclusive emphasis upon pathologic recognition of the disorder. The
Rituximab for the treatment of eosinophilic granulomatosis with polyangiitis (Churg–Strauss)
TLDR
The treatment of EGPA with rituximab resulted in high rates of improvement and reduced requirement of prednisolone, and may be considered for the treatment ofEGPA.
Churg-Strauss syndrome: evolving concepts.
TLDR
Progress is needed in Churg-Strauss syndrome's therapeutic management, and better understanding of the complex disease mechanisms may aid such a quest.
Allergic granulomatosis and angiitis (Churg-Strauss syndrome). Report and analysis of 30 cases.
TLDR
The clinical and morphologic findings of allergic granulomatosis and angiitis of Churg and Strauss in 21 men and 9 women were reviewed and Corticosteroids seem to influence long-term survival favorably.
Respiratory manifestations of eosinophilic granulomatosis with polyangiitis (Churg–Strauss)
TLDR
In EGPA, asthma is severe, antedates systemic manifestations by a mean of 12 years, and progresses to long-term persistent airflow obstruction despite corticosteroids in a large proportion of patients, which affects long- term management and morbidity.
Allergic granulomatosis and angiitis (Churg-Strauss syndrome). Report and analysis of 30 cases.
TLDR
The clinical and morphologic findings of allergic granulomatosis and angiitis of Churg and Strauss in 21 men and 9 women were reviewed and Corticosteroids seem to influence long-term survival favorably.
Childhood-onset Eosinophilic Granulomatosis with Polyangiitis (formerly Churg-Strauss Syndrome): A Contemporary Single-center Cohort
TLDR
Eosinophilia, in combination with upper airway, pulmonary, musculoskeletal, neurologic, and cardiac manifestations, is frequently observed in cEGPA.
Omalizumab in patients with eosinophilic granulomatosis with polyangiitis: a 36-month follow-up study
TLDR
In patients with EGPA and moderate to severe allergic asthma, omalizumab can be beneficial and safe and enables corticosteroid tapering while decreasing eosinophilia and improving asthma symptoms over 36 months.
Eosinophilic granulomatosis with polyangiitis (Churg-Strauss): clinical characteristics and long-term followup of the 383 patients enrolled in the French Vasculitis Study Group cohort.
TLDR
Although EGPA relapses remain frequent, mortality has declined, at least since 1996, and multivariable analysis identified cardiomyopathy, older age, and diagnosis during or prior to 1996 as independent risk factors for death and lower eosinophil count at diagnosis as predictive of relapse.
Rituximab in the treatment of refractory or relapsing eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome)
TLDR
Preemptive retreatment with RTX, combined with standard maintenance immunosuppressants, resulted in a sustained treatment response and rituximab proved to be an efficient and safe treatment for AN CA-positive and ANCA-negative patients.
...
...